Connor, Clark & Lunn Investment Management (CC&L)
RCKT icon

Connor, Clark & Lunn Investment Management (CC&L)’s Rocket Pharmaceuticals RCKT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-21,204
Closed -$338K – 1391
2022
Q3 		$338K Sell
21,204
-41,540
-66% -$648K ﹤0.01% 894
2022
Q2 		$863K Buy
+62,744
New +$748K 0.01% 653

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s RCKT Position: Q4 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Rocket Pharmaceuticals (RCKT) in Q4 2022, closing a stake of 21,204 shares — an estimated $338K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RCKT in Q2 2022 and held it in 2 quarters. The position peaked at $863K in Q2 2022. 168 funds tracked by Wall St. Rank hold RCKT as of Q4 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Rocket Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 21,204 Rocket Pharmaceuticals shares in Q4 2022, an estimated $338K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Rocket Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Rocket Pharmaceuticals position peaked at $863K in Q2 2022.
  • 168 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2022, filed 10 Feb 2023.